Your trusted source for investing success

Tag: infectious diseases

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report

Immuron Reports Positive Results in NASH Clinical Trial

Immuron (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the topline results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study.

As quoted in the press release:
A total of 133

ADMA Biologics Reports Full Year 2017 Financial Results

ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immmune deficiencies and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2017.

As quoted in the press release:
Adam Grossman,

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

Summit Therapeutics (NASDAQ:SMMT) the drug discovery and development company advancing therapies for rare diseases and infectious diseases, today announces positive 24-week interim results from the open-label Phase 2 proof of concept clinical trial, PhaseOut DMD. PhaseOut DMD is evaluating the utrophin modulator ezutromid in patients with Duchenne muscular dystrophy.

As quoted

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
5 Top NASDAQ Biotech Stocks: Second Sight Medical on Top